133 related articles for article (PubMed ID: 27272799)
1. Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
Yan S; Coffing BN; Li Z; Xie H; Brennick JB; Beg HA; Froehlich HM; Wells WA
Anticancer Res; 2016 Jun; 36(6):2871-80. PubMed ID: 27272799
[TBL] [Abstract][Full Text] [Related]
2. Expression of ProEx C in primary and metastatic urothelial carcinoma.
Liu L; Cohen C; Siddiqui MT
Diagn Cytopathol; 2015 Mar; 43(3):181-7. PubMed ID: 24975746
[TBL] [Abstract][Full Text] [Related]
3. Utility of ProEx C in the histologic evaluation of the neoplastic and nonneoplastic urothelial lesions.
Moatamed NA; Vergara-Lluri ME; Lu D; Apple SK; Kerkoutian S; Rao JY
Hum Pathol; 2013 Nov; 44(11):2509-17. PubMed ID: 24029711
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and prognostic value of glucose transporters in melanocytic lesions.
Ruby KN; Liu CL; Li Z; Felty CC; Wells WA; Yan S
Melanoma Res; 2019 Dec; 29(6):603-611. PubMed ID: 31135601
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical patterns of ProEx C in vulvar squamous lesions: detection of overexpression of MCM2 and TOP2A.
Chen H; Gonzalez JL; Brennick JB; Liu M; Yan S
Am J Surg Pathol; 2010 Sep; 34(9):1250-7. PubMed ID: 20697251
[TBL] [Abstract][Full Text] [Related]
6. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.
Pinheiro C; Miranda-Gonçalves V; Longatto-Filho A; Vicente AL; Berardinelli GN; Scapulatempo-Neto C; Costa RF; Viana CR; Reis RM; Baltazar F; Vazquez VL
Cell Cycle; 2016 Jun; 15(11):1462-70. PubMed ID: 27105345
[TBL] [Abstract][Full Text] [Related]
7. Topoisomerase II-alpha expression in melanocytic nevi and malignant melanoma.
Mu XC; Tran TA; Ross JS; Carlson JA
J Cutan Pathol; 2000 May; 27(5):242-8. PubMed ID: 10847549
[TBL] [Abstract][Full Text] [Related]
8. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Significance of Nuclear Phospho-ATM Expression in Melanoma.
Bhandaru M; Martinka M; McElwee KJ; Rotte A
PLoS One; 2015; 10(8):e0134678. PubMed ID: 26275218
[TBL] [Abstract][Full Text] [Related]
10. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
11. A pilot evaluation of a novel immunohistochemical assay for topoisomerase II-alpha and minichromosome maintenance protein 2 expression (ProEx C) in cervical adenocarcinoma in situ, adenocarcinoma, and benign glandular mimics.
Aximu D; Azad A; Ni R; Colgan T; Nanji S
Int J Gynecol Pathol; 2009 Mar; 28(2):114-9. PubMed ID: 19188825
[TBL] [Abstract][Full Text] [Related]
12. [Immunohistochemical markers for cytoplasmic antigens in acquired melanosis, malignant melanomas, and nevi of the conjunctiva].
Hitzer S; Bialasiewicz AA; Richard G
Klin Monbl Augenheilkd; 1998 Oct; 213(4):230-7. PubMed ID: 9848068
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic assessment of two novel proliferation-specific antigens in benign and malignant melanocytic lesions.
Rudolph P; Lappe T; Schubert C; Schmidt D; Parwaresch RM; Christophers E
Am J Pathol; 1995 Dec; 147(6):1615-25. PubMed ID: 7495287
[TBL] [Abstract][Full Text] [Related]
14. PRAME expression in cutaneous melanoma does not correlate with disease-specific survival.
Parra O; Ma W; Li Z; Coffing BN; Linos K; LeBlanc RE; Momtahen S; Sriharan A; Cloutier JM; Wells WA; Yan S
J Cutan Pathol; 2023 Oct; 50(10):903-912. PubMed ID: 37430414
[TBL] [Abstract][Full Text] [Related]
15. ProEx C stain analysis in recurrent respiratory papillomatosis.
Bhandarkar ND; Sims HS; David O
Ann Otol Rhinol Laryngol; 2010 Feb; 119(2):99-104. PubMed ID: 20336920
[TBL] [Abstract][Full Text] [Related]
16. ProEx C as an adjunct marker to improve cytological detection of urothelial carcinoma in urinary specimens.
Moatamed NA; Rao JY; Alexanian S; Cobarrubias M; Levin M; Lu D; Apple SK
Cancer Cytopathol; 2013 Jun; 121(6):320-8. PubMed ID: 23364848
[TBL] [Abstract][Full Text] [Related]
17. High expression of cytoplasmic phosphorylated CSE1L in malignant melanoma but not in benign nevi: phosphorylated CSE1L for the discrimination between melanoma and benign nevi.
Chin SY; Wu PR; Shih YH; Yeh CM; Lee WR; Shen SC; Yeh KT; Jiang MC; Tseng JT
Int J Clin Exp Pathol; 2015; 8(2):1393-401. PubMed ID: 25973023
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of p16INK4a, minichromosome maintenance protein 2, DNA topoisomerase IIalpha, ProEX C, and p16INK4a/ProEX C in cervical squamous intraepithelial lesions.
Shi J; Liu H; Wilkerson M; Huang Y; Meschter S; Dupree W; Schuerch C; Lin F
Hum Pathol; 2007 Sep; 38(9):1335-44. PubMed ID: 17512033
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]